This feature highlights changes in clinical trial organizations’ personnel. 

Achilles Therapeutics

Achilles Therapeutics has appointed Karl Peggs to the role of chief medical officer. Peggs is currently the professor of transplant science and cancer immunotherapy at the UCL Cancer Institute.

Atlantic Healthcare 

Nermeen Varawalla has been named chief medical officer and head of clinical development of Atlantic Healthcare. Formerly, Varawalla was senior vice president and head of clinical development at BTG International.

Bavarian Nordic

Bavarian Nordic has appointed Anu Kerns to the role of executive vice president of people and organizations. Kerns was most recently the global change and transformation lead at Novo Nordisk.

Dewpoint Therapeutics 

Ameet Nathwani has been appointed CEO of Dewpoint Therapeutics. His most recent appointments were chief medical officer, chief digital officer and executive committee member at Sanofi.

e-therapeutics 

Ali Mortazavi, former CEO of Silence Therapeutics, has taken the helm of e-therapeutics as its newest CEO.

Flagship Pioneering 

Tuyen Ong, former senior vice president and head of the ophthalmology franchise at Biogen, has been named CEO-partner of Flagship Pioneering. Ong will also hold a concurrent role of CEO at Ring Therapeutics.

Frazier Healthcare

Don Frail and Michael Varney have been added as senior advisers on the life sciences team at Frazier Healthcare. Most recently, Frail was senior vice president of R&D at Allergan, and Varney previously held the position of executive vice president and head of Genentech’s research and early development.

hyperCORE

hyperCORE, a clinical study site network, has appointed Karri Venn as its new CEO. Venn is also currently the president of research at LMC Healthcare.

Inozyme Pharma 

Inozyme Pharma has named Yves Sabbagh senior vice president and chief scientific officer. Sabbagh was most recently head of rare renal and musculoskeletal diseases research at Sanofi.

Inversago Pharma

Michael Harvey, who recently served as vice president of drug development and Montreal site head at Ipsen, has been named senior vice president of drug development at Inversago Pharma.

Jaguar Health

Melissa Yeager has been appointed senior vice president of regulatory affairs and quality assurance at Jaguar Health and its wholly owned subsidiary Napo Pharmaceuticals. Previously, Yeager was senior vice president of Alder BioPharmaceuticals.

Kedrion Biopharma

Val Romberg, former executive vice president of operations for CSL Behring, has been named CEO of Kedrion Biopharma.

MaxCyte

MaxCyte has hired Sarah Meeks to fill the role of vice president of business development and Steve Nardi to vice president of manufacturing and engineering operations. Meeks was most recently vice president of business development at Synpromics. Nardi joins MaxCyte from Iradimed, where he served as vice president of worldwide manufacturing. In addition, MaxCyte has promoted Brad Calvin from executive vice president of global commercial operations to the role of chief commercial officer.

Maze Therapeutics

Sarah Noonberg has been tapped by Maze Therapeutics to take the role of chief medical officer. Previously, Noonberg was chief medical officer of Nohla Therapeutics.

Medeor Therapeutics 

Daniel Brennan has been appointed to the role of chief medical officer of Medeor Therapeutics. Brennan will continue to serve in his current roles of inaugural medical director at the Comprehensive Transplant Center at Johns Hopkins Hospital and professor of nephrology at the Johns Hopkins Division of Renal Medicine.

Meissa Vaccines

Meissa Vaccines has named former senior vice president of business development at Portola Pharmaceuticals, William Daly, to the role of chief business officer. Meissa has also appointed Keith Wells to chief manufacturing officer. Wells was most recently a scientific and technical adviser to the Biomedical Advance Research and Development Authority.

Micron Medical

Micron Medical has appointed former MiMedx executive vice president and chief strategy officer, Mark Landy, to CEO.

Novavax

Novavax has promoted Russell Wilson to executive vice president and NanoFlu™ general manager. Wilson’s most recent role was senior vice president of business development, which he has held at Novavax since 2011.

OncoSec Medical 

Sandra Aung has been named senior vice president and chief clinical development officer of OncoSec Medical. Aung most recently served as the senior director of clinical development at Nektar Therapeutics.

Recce Pharmaceuticals 

Michele Dilizia has been named chief scientific officer of Recce Pharmaceuticals. Previously, Dilizia was the executive director of microbiology and regulatory affairs at Recce.

Sanofi

Frank Nestle has been named global head of research and chief scientific officer of Sanofi. Nestle was the former global head of immunology and inflammation, and chief scientific officer of North America at Sanofi.

SpectraWave

Cardiology-focused startup SpectraWave has appointed Eman Namati to CEO. Previously, Namati was CEO of NinePoint Medical.

SPI Pharma

Scott Thomson has been named CEO of SPI Pharma. Most recently, Thomson was senior vice president of the care chemicals division of North America at BASF.

Trevi Therapeutics

Trevi Therapeutics has made several new key appointments, including Shashank Rohatagi to vice president of pharmacology and clinical pharmacokinetics, Farrell Simon to vice president and head of U.S. marketing and Katherine Takaki to vice president of global regulatory affairs. Rohatagi was recently senior principal scientist for clinical pharmacology at Metrum Research Group, and Simon previously held the position of chief of staff to the group president of biopharma at Pfizer. Also, Takaki previously served as vice president of global regulatory affairs at Iterum Therapeutics.